Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci - PubMed (original) (raw)
. 2009 Apr 1;27(10):1627-36.
doi: 10.1200/JCO.2008.17.9432. Epub 2009 Mar 2.
Marc Remke, Axel Benner, Frank Mendrzyk, Grischa Toedt, Jörg Felsberg, Andrea Wittmann, Frauke Devens, Nicolas U Gerber, Stefan Joos, Andreas Kulozik, Guido Reifenberger, Stefan Rutkowski, Otmar D Wiestler, Bernhard Radlwimmer, Wolfram Scheurlen, Peter Lichter, Andrey Korshunov
Affiliations
- PMID: 19255330
- DOI: 10.1200/JCO.2008.17.9432
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci
Stefan Pfister et al. J Clin Oncol. 2009.
Abstract
Purpose: Medulloblastoma is the most common malignant brain tumor in children. Current treatment decisions are based on clinical variables. Novel tumor-derived biomarkers may improve the risk stratification of medulloblastoma patients.
Patients and methods: A model for the molecular risk stratification was proposed from an array-based comparative genomic hybridization (array-CGH) screen (n = 80). Fluorescence in situ hybridization (FISH) analyses for chromosome arms 6q, 17p, and 17q and the MYC and MYCN loci were performed in an independent validation set (n = 260). Copy number aberrations were correlated with clinical, histologic, and survival data.
Results: Gain of 6q and 17q and genomic amplification of MYC or MYCN were each associated with poor outcome in the array-CGH study (n = 80). In contrast, all patients with 6q-deleted tumors survived. Given these findings, the following hierarchical molecular staging system was defined: (1) MYC/MYCN amplification, (2) 6q gain, (3) 17q gain, (4) 6q and 17q balanced, and (5) 6q deletion. The prognostic value of this staging system was investigated by FISH analysis (n = 260). The addition of molecular markers to clinical risk factors resulted in the identification of a large proportion of patients (72 of 260 patients; 30%) at high risk for relapse and death who would be considered standard risk by application of clinical variables alone.
Conclusion: Genomic aberrations in medulloblastoma are powerful independent markers of disease progression and survival. By adding genomic markers to established clinical and histologic variables, outcome prediction can be substantially improved. Because the analyses can be conducted on routine paraffin-embedded material, it will be especially feasible to use this novel molecular staging system in large multicenter clinical trials.
Similar articles
- Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister SM. Korshunov A, et al. J Clin Oncol. 2010 Jun 20;28(18):3054-60. doi: 10.1200/JCO.2009.25.7121. Epub 2010 May 17. J Clin Oncol. 2010. PMID: 20479417 - Accumulation of genomic aberrations during clinical progression of medulloblastoma.
Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S. Korshunov A, et al. Acta Neuropathol. 2008 Oct;116(4):383-90. doi: 10.1007/s00401-008-0422-y. Epub 2008 Aug 15. Acta Neuropathol. 2008. PMID: 18704466 - Characteristics of medulloblastoma in children under age of three years.
Ryzhova MV, Zheludkova OG, Kumirova ÉV, Shishkina LV, Panina TN, Gorelyshev SK, Khukhlaeva EA, Mazerkina NA, Matuev KB, Medvedeva OA, Tarasova EM, Kholodov BV, Kapitul'skaia OIu. Ryzhova MV, et al. Zh Vopr Neirokhir Im N N Burdenko. 2013;77(1):3-10; discussion 11. Zh Vopr Neirokhir Im N N Burdenko. 2013. PMID: 23659115 English, Russian. - Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature.
Gilhuis HJ, Anderl KL, Boerman RH, Jeuken JM, James CD, Raffel C, Scheithauer BW, Jenkins RB. Gilhuis HJ, et al. Clin Neurol Neurosurg. 2000 Dec;102(4):203-209. doi: 10.1016/s0303-8467(00)00112-8. Clin Neurol Neurosurg. 2000. PMID: 11154805 Review. - Risk estimation of neuroblastoma patients using molecular markers.
Fischer M, Spitz R, Oberthür A, Westermann F, Berthold F. Fischer M, et al. Klin Padiatr. 2008 May-Jun;220(3):137-46. doi: 10.1055/s-2008-1065345. Klin Padiatr. 2008. PMID: 18478485 Review.
Cited by
- Survival-Related Genes on Chromosomes 6 and 17 in Medulloblastoma.
Vriend J, Liu XQ. Vriend J, et al. Int J Mol Sci. 2024 Jul 9;25(14):7506. doi: 10.3390/ijms25147506. Int J Mol Sci. 2024. PMID: 39062749 Free PMC article. - Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.
Hofman DA, Ruiz-Orera J, Yannuzzi I, Murugesan R, Brown A, Clauser KR, Condurat AL, van Dinter JT, Engels SAG, Goodale A, van der Lugt J, Abid T, Wang L, Zhou KN, Vogelzang J, Ligon KL, Phoenix TN, Roth JA, Root DE, Hubner N, Golub TR, Bandopadhayay P, van Heesch S, Prensner JR. Hofman DA, et al. Mol Cell. 2024 Jan 18;84(2):261-276.e18. doi: 10.1016/j.molcel.2023.12.003. Epub 2024 Jan 3. Mol Cell. 2024. PMID: 38176414 - Hallmark discoveries in the biology of Wilms tumour.
Perotti D, Williams RD, Wegert J, Brzezinski J, Maschietto M, Ciceri S, Gisselsson D, Gadd S, Walz AL, Furtwaengler R, Drost J, Al-Saadi R, Evageliou N, Gooskens SL, Hong AL, Murphy AJ, Ortiz MV, O'Sullivan MJ, Mullen EA, van den Heuvel-Eibrink MM, Fernandez CV, Graf N, Grundy PE, Geller JI, Dome JS, Perlman EJ, Gessler M, Huff V, Pritchard-Jones K. Perotti D, et al. Nat Rev Urol. 2024 Mar;21(3):158-180. doi: 10.1038/s41585-023-00824-0. Epub 2023 Oct 17. Nat Rev Urol. 2024. PMID: 37848532 Review. - Medulloblastomas in Pediatric and Adults.
Gorelyshev S, Medvedeva O, Mazerkina N, Ryzhova M, Krotkova O, Golanov A. Gorelyshev S, et al. Adv Exp Med Biol. 2023;1405:117-152. doi: 10.1007/978-3-031-23705-8_5. Adv Exp Med Biol. 2023. PMID: 37452937 - IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
Hagemann S, Misiak D, Bell JL, Fuchs T, Lederer MI, Bley N, Hämmerle M, Ghazy E, Sippl W, Schulte JH, Hüttelmaier S. Hagemann S, et al. Mol Cancer. 2023 May 29;22(1):88. doi: 10.1186/s12943-023-01792-0. Mol Cancer. 2023. PMID: 37246217 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources